首页> 美国卫生研究院文献>Journal for Immunotherapy of Cancer >A Phase I/III multicenter open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected stage IIIb-IV melanoma (MASTERKEY-265)

【2h】

A Phase I/III multicenter open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected stage IIIb-IV melanoma (MASTERKEY-265)

机译：talimogene laherparepvec（T-VEC）与pembrolizumab联合治疗未切除的IIIb-IV期黑色素瘤（MASTERKEY-265）的I / III期多中心开放标签试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

期刊名称 Journal for Immunotherapy of Cancer
作者
Georgina V Long; Reinhard Dummer; Antoni Ribas; Igor Puzanov; Olivier Michielin; Ari VanderWalde; Robert HI Andtbacka; Jonathan Cebon; Eugenio Fernandez; Josep Malvehy; Anthony J Olszanski; Thomas F Gajewski; John M Kirkwood; Olga Kuznetsova; Lisa Chen; David R Kaufman; Jeffrey Chou; F Stephen Hodi;
展开▼
作者单位

展开▼
年(卷),期 2015(3),Suppl 2
年度 2015
页码 P181
总页数 2
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265) [J] . Georgina V Long, Reinhard Dummer, Antoni Ribas, Journal for ImmunoTherapy of Cancer . 2015,第S2期

机译：talimogene laherparepvec（T-VEC）与pembrolizumab联合治疗未切除的IIIb-IV期黑色素瘤的I / III期，多中心，开放标签试验（MASTERKEY-265）
2. Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma [J] . Igor Puzanov, Mohammed Milhem, Robert Andtbacka, Journal for ImmunoTherapy of Cancer . 2013,第S1期

机译：1b / 2的相1结果，多中心，开放标签试验，以评估Talimogene Laherparepvec（T-Vec）和IpiLimumab（IPI）的安全性和疗效在以前未经治疗的未分辨阶段IV黑色素瘤中单独使用
3. Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial [J] . Howard L Kaufman, Robert HI Andtbacka, Frances A Collichio, Journal for ImmunoTherapy of Cancer . 2014,第S3期

机译：在Talimogene Laherparepvec（T-VEC）进行的III期OPTiM试验中，未切除的IIIb-IV期黑色素瘤患者的持久反应（DR）与总体生存（OS）之间的关联
4. Long-term effects of laser-imiquimod combination in the treatment of late-stage melanoma patients [C] . Mark F. Naylor, Wei R. Chen Biophotonics and immune responses VII. . 2012

机译：咪喹莫特激光联合治疗晚期黑色素瘤患者的远期疗效
5. A Study of Erlotinib Monotherapy and in Combination with Pembrolizumab in Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [D] . Liu, Qiong. 2021

机译：Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
6. Phase 1 results of a phase 1b/2 multicenter open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated unresected stage IIIB-IV melanoma [O] . Igor Puzanov, Mohammed Milhem, Robert Andtbacka, 2013

机译：1b / 2期多中心开放标签试验的1期结果用于评估talimogene laherparepvec（T-VEC）和ipilimumab（ipi）与单独ipi在先前未经治疗未切除的IIIB-IV期黑色素瘤中的安全性和有效性
7. A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265) [O] . 2015

机译：talimogene laherparepvec（T-VEC）与pembrolizumab联合治疗未切除的IIIb-IV期黑色素瘤（MASTERKEY-265）的I / III期，多中心，开放标签试验

A Phase I/III multicenter open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected stage IIIb-IV melanoma (MASTERKEY-265)

著录项

引文网络

相似文献

相关主题

期刊订阅